



RELEVANT EVENT

LLEIDANETWORKS SERVEIS TELEMÀTICS, S.A.

Resolutions of the Ordinary and Extraordinary General Shareholders' Meeting of Lleida.net held on 5 June 2025

In accordance with the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse, Article 227 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity regarding the information to be provided by Growth Companies, LLEIDANETWORKS SERVEIS TELEMÀTICS S.A.: (hereinafter "Lleida.net" or the "Company" or the "Enterprise") brings to your attention the following information that has been prepared under the exclusive responsibility of the issuer and its administrators:

The General Shareholders Meeting of LLEIDANETWORKS SERVEIS TELEMÀTICS S.A., held AYER, June 9, 2025, on first call, with the attendance of 38 shareholders, of whom 10 attended personally and 28 were represented. In total, almost 50.33% of the subscribed capital with voting rights **have unanimously approved all the proposed resolutions** that the Company's Board of Directors had agreed to submit to its deliberation and decision:

Agenda of the ORDINARY SHAREHOLDER'S MEETING

First. Review and potential approval of the Company's Individual Annual Accounts (including Balance Sheet, Profit and Loss Statement, Statement of Changes in Equity, Cash Flow Statements, and Management Report) for the fiscal year ending December 31, 2024, along with the audit report.

It was unanimously agreed to approve the Company's individual annual accounts for the financial year ended 31 December 2024, as audited by the Company's statutory auditors.

Second. – Review and potential approval of the Company's Individual Annual Accounts (including Balance Sheet, Profit and Loss Statement, Statement of Changes in Equity, Cash Flow Statements, and Management Report) for the fiscal year ending December 31, 2024, along with the audit report.

It was unanimously agreed to approve the Company's consolidated annual accounts for the financial year ended 31 December 2024, as audited by the Company's statutory auditors.



Third. - Approval, where appropriate, of the proposed allocation of the Company's result for the financial year ended 31 December 2024

It was unanimously agreed to allocate the result of the individual annual accounts, amounting to €1,090,119.36, to accumulated losses from previous financial years.

Fourth. – Evaluation and potential approval of the Company's management and actions taken by the Board of Directors during the fiscal year ending December 31, 2024.

With 85.74% of votes in favour and 14.26% abstentions, the shareholders approved the management and actions of the Board of Directors for the financial year ended 31 December 2024 and granted discharge to its members for said period.

Agenda of the EXTRAORDINARY SHAREHOLDER'S MEETING

First. – Determination of the number of members of the Board of Directors.

It was unanimously agreed to increase the number of Board members from the current eight (8) to ten (10), in line with Article 15 of the Company's Articles of Association, which states that the Board shall comprise no fewer than three (3) and no more than twelve (12) directors.

This decision was taken ahead of the discussion and voting on appointments and reappointments of Board members, which followed under subsequent agenda items.

Second. – Voluntary resignation of Ms Beatriz García Torre and Mr Jordi Carbonell i Sebarroja as members of the Board of Directors.

The meeting acknowledged the voluntary resignations of Ms Beatriz García Torre and Mr Jordi Carbonell i Sebarroja from their positions on the Board, effective as of the date of the meeting, upon completion of the five-year term for which they were appointed.

The Board expressed its appreciation to both directors for their service, recognising their commitment and contributions to the Company's progress.

Third. – Re-election, where applicable, of members of the Board of Directors whose term of office expires.

It is adopted unanimously:



Re-elect and appoint, as a member of the Board of Directors, effective June 9, 2025 and for the statutory period of five (5) years. Mrs. ARRATE MARÍA USANDIZAGA RUIZ, as executive director.

Re-elect and appoint, as a member of the Board of Directors, effective June 9, 2025 and for the statutory period of five (5) years MR FRANCISCO SAPENA SOLER as executive director

Re-elect and appoint, as a member of the Board of Directors, effective June 9, 2025 and for the statutory period of five (5) years, Mr. MARCOS GALLARDO MESEGUER as external director.

Re-elect and appoint, as a member of the Board of Directors, effective June 9 2025 and for the statutory period of five (5) years Jorge SAINZ DE VICUÑA as independent director.

Re-elect and appoint, as a member of the Board of Directors, effective June 9, 2025 and for the statutory period of five (5) years MR ANTONIO LÓPEZ DEL CASTILLO as independent director.

Re-elect and appoint, as a member of the Board of Directors, effective June 9, 2025 and for the statutory period of five (5) years MIGUEL PÉREZ SUBÍAS as independent director.

Each of the re-elected directors and the ratified director accept their appointment as members of the Board, undertaking to carry out their duties well and faithfully and declare that they are not involved, directly or indirectly, in any of the causes of incompatibility or prohibition set forth in the Law, the By-laws and the Regulations of the Board of Directors.

Prior to this General Meeting, the Board of Directors reviewed the category of the new Director named herein in order to verify compliance with the requirements for their appointment under such category, all pursuant to the provisions of article 529 duodecies of the Law on Corporations. It is hereby expressly placed on the record that the company is not required to assign the categories referred to in article 529 k to its Directors to the extent said rule only applies to companies whose shares are listed in official secondary markets. It does not apply to companies with shares listed in the BME Growth

The reappointments were made in accordance with Article 16 of the Company's Articles of Association and applicable regulations, with everyone retaining their previous director category.

Fourth. – Appointment, upon proposal of the Board of Directors dated 29 April 2025, of Ms Anna Bisart Rosell as independent director.



It was unanimously agreed to appoint Ms Anna Bisart Rosell, of legal age and Spanish nationality, as an independent director for the statutory term of five (5) years, with effect from today's date.

The new member of the Board of Directors is present and accepts the appointment herein, stating not to have been declared ineligible for this office.

Fifth. – Appointment, upon proposal of the Board of Directors dated 29 April 2025, of Ms Teresa Reales Peinado as independent director.

It was unanimously agreed to appoint Ms Teresa Reales Peinado, of legal age and Spanish nationality, as an independent director for the statutory term of five (5) years, with effect from today's date.

The new member of the Board of Directors is present and accepts the appointment herein, stating not to have been declared ineligible for this office.

Sixth. – Appointment, upon proposal of the Board of Directors dated 29 April 2025, of Ms Ana Serrano Oñate as independent director.

It was unanimously agreed to appoint Ms Ana Serrano Oñate, of legal age and Spanish nationality, as an independent director for the statutory term of five (5) years, with effect from today's date.

The new member of the Board of Directors is present and accepts the appointment herein, stating not to have been declared ineligible for this office.

Seventh. – Appointment, upon proposal of the Board of Directors dated 29 April 2025, of Ms Sílvia Cunill Calvet as independent director.

It was unanimously agreed to appoint Ms Silvia Cunill Calvet, of legal age and Andorran nationality, as an independent director for the statutory term of five (5) years, with effect from today's date.

The new member of the Board of Directors is present and accepts the appointment herein, stating not to have been declared ineligible for this office.

Prior to this General Meeting, the Board of Directors reviewed the category of the new Director named herein to verify compliance with the requirements for their appointment under such category, all pursuant to the provisions of article 529 duodecies of the Law on Corporations. It is hereby expressly placed on the record that the company is not required to assign the categories referred to in article 529 k to its Directors to the extent said rule only applies to



companies whose shares are listed in official secondary markets. It does not apply to companies with shares listed in the Spanish Alternative Investment Market.

Eighth. – Appointment of the statutory auditor for the financial years 2025, 2026 and 2027.

It was unanimously agreed to appoint the firm PKF ATTEST SERVICIOS EMPRESARIALES, S.L., with registered office at Alameda de Recalde, 36, 8th floor, 48009 Bilbao Companies Register of Bizkaia, and tax identification number B-95221271, as statutory auditor to carry out the audit of the Company's individual and consolidated annual accounts for the financial years ending on 31 December 2025, 2026 and 2027.

Ninth. Authorisation to request the delisting of the Company's shares from the OTC QX market in the United States.

With 85.74% of votes in favour and 14.26% abstentions, the General Meeting authorised the Board of Directors, with the fullest powers permitted by law, to request the voluntary delisting of the Company's shares from the Over-the-Counter QX Market (OTC QX) in the United States, where they are currently admitted to trading.

This resolution is based on grounds of corporate interest, due to the low liquidity and trading volume of the Company's shares on said market, as well as the administrative burden and associated costs of maintaining the listing.

Tenth. Consultative voting on the annual report concerning the remuneration of the directors for the fiscal year 2024.

With 85.74% of votes in favour and 14.26% abstentions, the shareholders approved the Annual Directors' Remuneration Report corresponding to the 2024 financial year by way of an advisory vote.

Eleventh .– Amendment of the remuneration scheme of the Board of Directors to include:

***(i) a profit-sharing component, establishing the applicable maximum percentage, and
(ii) the delivery of shares in the Company. Consequently, amendment of Article 18 of the Company's Articles of***

It was resolved to approve, by a majority of 85.74% of votes in favour and 14.26% abstentions, the following

- i) A variable cash remuneration scheme, subject to the following terms and conditions:
This remuneration will accrue if the Consolidated Profit Before Tax exceeds that of*



the previous financial year by at least 10%, provided that the legal and statutory reserves have been duly covered and a minimum dividend of 4% of the nominal value of the shares has been distributed to shareholders. The amount shall become payable once the Consolidated Annual Accounts for the financial year have been approved, together with an unqualified Auditor's Report. All members of the Board of Directors shall be entitled to this remuneration. The total amount of the variable remuneration under this scheme shall be equivalent to 5% of the Consolidated Profit Before Tax and will be distributed in equal parts among all directors in office at the end of the financial year for which the Consolidated Annual Accounts are approved.

- ii) *A long-term share-based incentive plan, governed by the following terms and conditions: The incentive will accrue solely by virtue of having held office as director for a period of 3, 4 or 5 years. The plan will be implemented through the delivery of shares in the Company during years 3, 4 and 5 from the date of acceptance of the plan by each director, with the Company applying the relevant cash withholding at each stage. The plan shall apply to independent directors, executive directors and the Director-Secretary. It shall not apply to proprietary directors, those subject to legal incompatibility, or corporate directors (i.e. legal entity directors). Nor shall it apply to directors that are legal entities. In the event of termination of a director's position, the incentive for the next scheduled vesting date will still accrue, provided the termination is not due to breach of director duties or a subsequent legal incompatibility. Upon completion of year 3, 20,000 shares shall vest; upon completion of year 4, an additional 25,000 shares; and upon completion of year 5, a further 30,000 shares. Full implementation of the plan would result in the delivery of 750,000 shares to the Board as a whole, equivalent to 4.67% of the Company's share capital. The Company may defer payment if, on the relevant vesting date, the consolidated net result for the financial year is insufficient to cover the amount accrued. In such cases, shares shall be valued either at market price on the vesting date or at historical cost if held in treasury and that value is lower. A condition for vesting shall be that the consolidated EBITDA for the most recent closed financial year is not less than €3,000,000 and that the consolidated net profit for the year is not less than €1,000,000.*

Therefore, it is hereby unanimously agreed by to modify article 18 of the company's Articles of Association, which shall now be worded as follows:

“Article 18.- Remuneration for Board Members. The members of the Board of Directors, in their capacity as directors and by virtue of the supervisory and collective decision-making duties inherent to the Board, are entitled to receive remuneration. Such remuneration shall consist of a fixed amount and attendance fees. In addition to the aforementioned amounts, directors' remuneration may also include a variable component and the delivery of shares in the Company. The implementation of such remuneration schemes must be approved by the General Shareholders' Meeting. At a minimum, the resolution adopted by the General Meeting shall determine, where applicable, the number of shares to be granted, the reference value of such



shares, and the duration of the remuneration scheme, together with any other terms and conditions deemed appropriate. The maximum annual aggregate remuneration payable to directors in their capacity as such shall be approved by the General Shareholders' Meeting and shall remain in force until such time as the Meeting resolves to amend it. The amount fixed by the General Meeting for directors' remuneration shall be allocated among the members of the Board as the Board of Directors may deem appropriate, considering each director's responsibilities, advisory roles, and level of dedication to the Company. This may result in different levels of remuneration for each director, as well as variations in frequency and form, including fees and benefits in kind. Regardless of the foregoing, directors entrusted with executive functions in the Company shall be entitled to receive specific remuneration for the performance of those functions, to be determined by the Board of Directors. This shall include a fixed component, a variable complementary component, and a welfare component, which may comprise appropriate pension and insurance schemes. In the event of termination not resulting from a breach of duties, the executive director shall be entitled to severance compensation. In all cases, the assignment of executive duties and the applicable terms and conditions shall be governed by a contract entered between the Company and the director. Such contract shall comply with the Company's remuneration policy, as approved, where applicable, by the General Shareholders' Meeting

Article 12. -Delegation of powers to formalise, execute and register the resolutions adopted by the General Board.

Approved by a majority of 85.74% in favour and 14.26% abstentions, it was resolved to authorise, as required by law, the Chairman, Mr Francisco Sapena Soler, the Secretary of the Board, Mr Marcos Gallardo Meseguer, and the remaining members of the Board, so that any of them, acting individually, may execute the foregoing resolutions as public instruments and carry out their full implementation, with the broadest powers to rectify and supplement as necessary.

Thirteenth. – Any other business.

There were no questions or requests.

Fourteenth. – - Drafting, reading and approval, where appropriate, of the minutes of the meeting.

Once the aforementioned resolutions had been approved, the meeting was briefly adjourned to allow the Secretary to draw up the minutes. These were then read aloud to those present, unanimously approved, signed by the Secretary with the Chairman's approval and signature, and sent by email to all attending shareholder



Lleida.net

La Primera Operadora Certificadora

ES: https://investors.lleida.net/docs/es/20250666_HRelev.pdf

We are available for any further clarification or detailed discussion you might require.

Kind regards,

Francisco Sapena Soler

CEO and Chairman of the Board